Health care resources utilisation and costs in patients with non-IPF progressive fibrosing interstitial lung disease

A. Olson (Denver, United States of America), T. Maher (London, United Kingdom), M. Salisbury (Ann Arbor, United States of America), V. Acciai (Ingelheim am Rhein, Germany), B. Mounir (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), L. Zouad-Lejour (Ingelheim am Rhein, Germany), C. Wells (Burlington, United States of America), A. Fischer (Denver, United States of America)

Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Session: CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Session type: Poster Discussion
Number: 3658
Disease area: Interstitial lung diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Olson (Denver, United States of America), T. Maher (London, United Kingdom), M. Salisbury (Ann Arbor, United States of America), V. Acciai (Ingelheim am Rhein, Germany), B. Mounir (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), L. Zouad-Lejour (Ingelheim am Rhein, Germany), C. Wells (Burlington, United States of America), A. Fischer (Denver, United States of America). Health care resources utilisation and costs in patients with non-IPF progressive fibrosing interstitial lung disease. 3658

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: